Acutaas Chemicals Ltd
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
- Market Cap ₹ 13,781 Cr.
- Current Price ₹ 1,683
- High / Low ₹ 1,868 / 754
- Stock P/E 61.1
- Book Value ₹ 173
- Dividend Yield 0.09 %
- ROCE 19.8 %
- ROE 15.9 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 41.2% CAGR over last 5 years
Cons
- Stock is trading at 9.73 times its book value
- Promoter holding has decreased over last quarter: -3.30%
- Company has a low return on equity of 13.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 160 | 188 | 236 | 240 | 341 | 520 | 617 | 688 | 990 | 1,086 | |
| 137 | 158 | 193 | 198 | 259 | 415 | 493 | 580 | 765 | 788 | |
| Operating Profit | 23 | 31 | 43 | 42 | 81 | 105 | 123 | 108 | 225 | 298 |
| OPM % | 14% | 16% | 18% | 18% | 24% | 20% | 20% | 16% | 23% | 27% |
| 0 | 3 | 1 | 2 | 0 | 3 | 4 | -18 | 18 | 33 | |
| Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 | 2 |
| Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 15 | 24 | 27 |
| Profit before tax | 19 | 28 | 37 | 35 | 72 | 91 | 112 | 69 | 214 | 302 |
| Tax % | 35% | 35% | 33% | 21% | 25% | 21% | 26% | 37% | 25% | |
| 12 | 18 | 25 | 27 | 54 | 72 | 83 | 44 | 160 | 226 | |
| EPS in Rs | 40.17 | 61.43 | 11.73 | 13.08 | 8.57 | 9.87 | 11.43 | 5.92 | 19.48 | 27.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% | 25% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 24% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 41% |
| 3 Years: | 30% |
| TTM: | 128% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| 1 Year: | 123% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 14% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 | 41 |
| Reserves | 38 | 56 | 71 | 97 | 132 | 482 | 550 | 638 | 1,271 | 1,376 |
| 26 | 41 | 54 | 59 | 137 | 1 | 3 | 203 | 11 | 8 | |
| 43 | 56 | 77 | 61 | 110 | 136 | 169 | 193 | 215 | 246 | |
| Total Liabilities | 109 | 155 | 212 | 228 | 410 | 655 | 759 | 1,071 | 1,538 | 1,671 |
| 14 | 15 | 58 | 62 | 161 | 178 | 222 | 357 | 499 | 613 | |
| CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 | 125 |
| Investments | 15 | 21 | 28 | 28 | 33 | 33 | 33 | 68 | 70 | 119 |
| 68 | 89 | 124 | 126 | 216 | 440 | 474 | 521 | 839 | 814 | |
| Total Assets | 109 | 155 | 212 | 228 | 410 | 655 | 759 | 1,071 | 1,538 | 1,671 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 29 | 10 | 22 | 27 | 27 | -10 | 56 | 101 | 116 | |
| -19 | -27 | -25 | -24 | -101 | -122 | -20 | -337 | -234 | |
| -7 | 14 | 3 | 0 | 72 | 140 | -14 | 235 | 274 | |
| Net Cash Flow | 2 | -2 | -0 | 3 | -2 | 8 | 21 | -1 | 155 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 97 | 113 | 80 | 127 | 113 | 136 | 113 | 107 |
| Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 135 | 116 |
| Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 153 | 119 | 104 |
| Cash Conversion Cycle | 11 | 31 | 40 | 83 | 78 | 105 | 114 | 129 | 119 |
| Working Capital Days | 46 | 59 | 23 | 29 | 49 | 139 | 138 | 89 | 122 |
| ROCE % | 38% | 35% | 27% | 33% | 24% | 21% | 14% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
1d - Earnings call transcript for the conference call held on October 17, 2025 post announcement of the financial results for the quarter and half year ended …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
18 Oct - Newspaper Publication of unaudited financial results of the Company for the second quarter and half year ended September 30, 2025 is attached.
-
Recording Of Earnings Conference Call Held On October 17, 2025
17 Oct - Earnings call recording of Oct 17, 2025 (3:30 PM IST) available on Acutaas website.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Oct - Q2 FY26 revenue ₹3,062mn (+24.1% YoY); EBITDA ₹953mn (31.1%); PAT ₹719mn; FY26 ~25% revenue growth guidance.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
17 Oct - Investor presentation discussing the Q2FY 26 unaudited financial results is herewith enclosed
Annual reports
Concalls
-
Oct 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
Business Overview
AMI Organics manufactures specialty chemicals with varied end usage, and is focused on development and manufacturing of advanced pharmaceutical intermediates for regulated and generic APIs and New Chemical Entities (NCE), and key starting materials for agrochemical and fine chemicals. [1]